The Cardiac Arrhythmia Suppression Trial

Robert J. Myerburg, Kenneth M. Kessler, Ronald J. Prineas, Jack L. Snitzer, John W. Fornace, Georg Schmidt, Kurt Ulm, Petra Barthel, John S. Flax, Andrew Cg Uprichard, A. David Canter, Jeremy N. Ruskin

Research output: Contribution to journalLetter

20 Scopus citations

Abstract

To the Editor: Some proarrhythmia must be expected with the use of all antiarrhythmic drugs. The results of any antiarrhythmic drug trial should therefore be considered in terms of an antiarrhythmia-proarrhythmia equilibrium, with beneficial outcome being an expression of the extent to which antiarrhythmic efficacy exceeds deaths from proarrhythmia. The risk inherent to the study population, provided by mortality figures from the placebo groups, is a major factor in establishing the balance. The Multicenter PostInfarction Research Group study1and the Cardiac Arrhythmia Pilot Study2provided meticulous preparation for an interventional trial, but the outcome of the Cardiac Arrhythmia Suppression Trial. . .

Original languageEnglish (US)
Pages (from-to)1754-1756
Number of pages3
JournalNew England Journal of Medicine
Volume321
Issue number25
DOIs
StatePublished - Dec 21 1989

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The Cardiac Arrhythmia Suppression Trial'. Together they form a unique fingerprint.

  • Cite this

    Myerburg, R. J., Kessler, K. M., Prineas, R. J., Snitzer, J. L., Fornace, J. W., Schmidt, G., Ulm, K., Barthel, P., Flax, J. S., Uprichard, A. C., Canter, A. D., & Ruskin, J. N. (1989). The Cardiac Arrhythmia Suppression Trial. New England Journal of Medicine, 321(25), 1754-1756. https://doi.org/10.1056/NEJM198912213212510